Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma - Wikidata - wikimedia - TriplyDB

Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma

Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma

http://www.wikidata.org/entity/Q28266655

about

Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma Novel agents in the treatment of multiple myeloma: a review about the future Multiple myeloma in the very elderly patient: challenges and solutions Monoclonal antibodies targeting CD38 in hematological malignancies and beyond Minimal Residual Disease Assessment in the Context of Multiple Myeloma Treatment The Role of Immunotherapy in Multiple Myeloma Natural Killer Cell-Based Therapies Targeting Cancer: Possible Strategies to Gain and Sustain Anti-Tumor Activity Development of Novel Immunotherapies for Multiple Myeloma The Role of Panobinostat Plus Bortezomib and Dexamethasone in Treating Relapsed or Relapsed and Refractory Multiple Myeloma: A European Perspective Recent advances in understanding multiple myeloma Recent advances in multiple myeloma: a Korean perspective The tumor microenvironment in esophageal cancer Glypican-3 Targeting Immunotoxins for the Treatment of Liver Cancer Triplet combinations in relapsed/refractory myeloma: update on recent phase 3 trials.The next generation of novel therapies for the management of relapsed multiple myeloma.The role of SLAMF7 in multiple myeloma: impact on therapy.Elotuzumab: a novel immune-stimulating therapy to treat multiple myeloma.Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma.Bendamustine, lenalidomide and dexamethasone (BRd) has high activity as 2nd -line therapy for relapsed and refractory multiple myeloma - a phase II trial.Systematic review and meta-analysis of the efficacy and safety of novel monoclonal antibodies for treatment of relapsed/refractory multiple myeloma.Immunotherapy in hematologic malignancies: past, present, and future.Interferon-alpha-based immunotherapies in the treatment of B cell-derived hematologic neoplasms in today's treat-to-target era Daratumumab: First Global Approval.Spleen Tyrosine Kinase Is Involved in the CD38 Signal Transduction Pathway in Chronic Lymphocytic Leukemia.Daratumumab monotherapy compared with historical control data in heavily pretreated and highly refractory patients with multiple myeloma: An adjusted treatment comparison.Multiple myeloma in the marrow: pathogenesis and treatments.Occurrence and prognostic significance of cytogenetic evolution in patients with multiple myeloma.Drug Monographs: Daratumumab and Osimertinib.APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment.Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma.Darzalex (Daratumumab): First Anti-CD38 Monoclonal Antibody Approved for Patients with Relapsed Multiple Myeloma The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia.Risk stratification, treatment selection, and transplant eligibility in multiple myeloma: a qualitative study of the perspectives and self-reported practices of oncologists.Multiple myeloma: 2016 update on diagnosis, risk-stratification, and management.The Singapore Myeloma Study Group Consensus Guidelines for the management of patients with multiple myeloma.Potent in vitro and in vivo effects of polyclonal anti-human-myeloma globulins.Posttransplant maintenance therapy in multiple myeloma: the changing landscape.Advances in targeted therapy for the treatment of patients with relapsed/refractory multiple myeloma.Novel Immunotherapies for Multiple Myeloma.Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trial.

P2860

Q26745919-2A35EAE4-5BCE-40AC-AE64-0D2CC93248AA Q26745924-C47BB44B-688A-4B94-9B72-90615D62B161 Q26752991-E99A3C10-088A-4A58-AC19-18C44A58114C Q26766718-C0F5F9E0-1D3C-4888-80F1-03572E6D44CF Q26768653-D9241231-21E5-45FC-B832-0F892D7D3E1B Q26771144-F700827A-9A97-4D76-800A-8EC4EF58CB62 Q26773135-052A7759-2EC2-4D79-A4D8-9854AB05C69E Q28066890-41E6E7FF-0FCB-4CA3-BFF1-24B91EC74AD0 Q28069789-7D31EC32-6E7A-43C2-9D30-D46B5D9A6FAB Q28070331-029BE69E-FCFF-480D-AC78-47A8DD34BB7B Q28074521-D44F394D-3C14-4479-A359-F5F8935061D8 Q28077074-F0DF43D1-F2F5-4220-BB11-778B138F7243 Q28077270-D52A71CC-0026-4F00-A87A-3182ECCECB01 Q30238893-7021543D-2AA3-4413-B940-DC42EBED3E17 Q30248534-161CB16B-C549-45A9-947B-1D7EC036CA91 Q30249167-D623A380-3D2C-4FBE-B68C-9F1C0AE92FD8 Q30249513-F99E54C3-DDD8-4E53-8FCE-BDEBC980D0A6 Q33434683-63219DA0-2398-4A1F-84DB-49BC68464BDD Q33437691-BC9FF4EF-E88A-419C-9126-879457C6DF80 Q33441476-520E5FF2-3C05-434A-AE3F-740A6C6F594D Q33593865-D2AA1299-4006-4ABD-8ED1-2B9FBF2E3EC2 Q33909086-DFC423D7-9D2C-4D25-BC69-FEA392C68F7D Q34507354-40B938C6-DE1E-4955-993E-350890330E02 Q36236545-472EBA0D-37C0-454B-B7BF-518ACAD33282 Q36363958-5B7FFB7B-4AD4-4C35-8026-19BD0EEC28F9 Q36725401-D98592C7-DB71-45B5-B589-8DE68794DEFA Q36754816-1ACAD268-ACE5-455C-BFBA-7D1B18DC4BA5 Q36977185-FA7F2206-AC18-4803-BDEA-0E80E3DB4D1A Q37035836-2A7EAE2D-20E8-4EFE-830F-63DD3B970BE7 Q37076421-A4865939-4A8A-43C3-8A58-F4D533482FC8 Q37237708-6D96BE72-4168-4D4B-BD98-87CAFAF8883A Q37517482-59E4C52E-4E1B-4ADF-AA02-A34A7CF44A86 Q37524970-81EBE710-AAC3-4C39-B387-2D1899FBD6E6 Q37623809-D0F64B85-A098-43A0-AA1D-4A1FC06DAF31 Q37644252-05E15804-768D-4CE8-B30A-043C70BE1DB3 Q37687119-8B0CFF95-31B2-4F1E-9364-AEA0E79A4DCF Q37737800-7B4DFF96-F39E-4935-8AA9-889F98096AD3 Q38630472-BC7F1D83-3A1A-4FE8-8003-EE16CA5ED3D5 Q38640444-322D4886-6555-4A23-8480-B348CA7E606E Q38650700-520952F9-D07F-4C3A-91B2-4D60BDD12C95

P2860

Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma

http://www.wikidata.org/entity/Q28266655

description

2015 nî lūn-bûn

@nan

2015 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma

@ast

Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma

@en

Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma

@nl

type

label

Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma

@ast

Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma

@en

Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma

@nl

prefLabel

Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma

@ast

Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma

@en

Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma

@nl

P1433

Q28266655-39853FCE-94E8-440D-9362-DC2609DCD017

P1476

Q28266655-F3E40B29-F070-4E57-87F1-2AA22E3C89CD

P2093

Q28266655-1EC2E115-DF8E-4B77-8536-D177CECEDF71

Q28266655-30FC82EC-28EC-4CDB-898F-87A3880B9A2A

Q28266655-35570655-21E5-4054-8228-FCEEEC97F28E

Q28266655-3ADF010D-8159-4002-BD6D-041FC469332A

Q28266655-3EBAC421-7172-44B4-A70A-EA0C86CE56C5

Q28266655-48DDCCC4-3CA3-4FAD-AC01-ECFCFD4F29CE

Q28266655-71CF6C45-32F4-461E-AB6A-0EE04E89E772

Q28266655-82502530-9F8C-45B3-B073-99D0995158AF

Q28266655-832FBA56-A6EE-4DC3-95A7-70ADB0B3C126

Q28266655-957614F3-976C-404C-8965-64BE5CC82CE1

P304

Q28266655-BCBA0007-522D-40BA-A669-D1A5AD9C257A

P31

Q28266655-5677C756-F48B-4278-AE8D-F3BE6A53C341

P3181

Q28266655-12C11DD9-98F2-4C23-84FD-EDE95134320E

P356

Q28266655-ADB6D4E6-A6A3-4554-88BB-93F555A242FA

P407

Q28266655-39E904ED-1114-4870-9291-45A4019CAB71

P433

Q28266655-A332279E-B7DD-4CE7-BA0E-AF3D6D9A1308

P478

Q28266655-5AF15720-E949-4F21-AC83-47625921A686

P50

Q28266655-1D666326-0B19-4BB9-BC16-6E893BCFF0FA

Q28266655-210382BF-C7A7-4CC8-B5BC-9DBEFCFA055E

Q28266655-521EBAD4-0F22-4B59-A405-62E38ECD5523

Q28266655-83F3BAA1-96B4-44ED-A15D-C087E7672E1B

Q28266655-E241FDDD-BC11-4941-9E3F-6DAE929198F5

P577

Q28266655-7B471EA6-59CE-4552-8FFE-48DFA360FA29

P698

Q28266655-1EE5B7C1-5B41-4E9C-9EAE-3990076CD58E

P3181

P356

P1433

The New England Journal of Medicine

P1476

Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma

@en

P2093

A Kate Sasser

http://www.w3.org/2001/XMLSchema#string

Clarissa M Uhlar

http://www.w3.org/2001/XMLSchema#string

Henk M Lokhorst

http://www.w3.org/2001/XMLSchema#string

Imran Khan

http://www.w3.org/2001/XMLSchema#string

Jacob P Laubach

http://www.w3.org/2001/XMLSchema#string

Jianping Wang

http://www.w3.org/2001/XMLSchema#string

Linda Basse

http://www.w3.org/2001/XMLSchema#string

Markus Hansson

http://www.w3.org/2001/XMLSchema#string

Monique C Minnema

http://www.w3.org/2001/XMLSchema#string

Nedjad Losic

http://www.w3.org/2001/XMLSchema#string

P304

1207-1219

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

334649

http://www.w3.org/2001/XMLSchema#string

P356

10.1056/NEJMOA1506348

http://www.w3.org/2001/XMLSchema#string

P407

P433

13

http://www.w3.org/2001/XMLSchema#string

P478

373

http://www.w3.org/2001/XMLSchema#string

P50

Antonio Palumbo

Paul G Richardson

P577

2015-09-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26308596

http://www.w3.org/2001/XMLSchema#string